A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

NCT03150602 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T Cell Lymphoma
Progression, Disease

Interventions

DRUG: Pralatrexate

Sponsor

Taiwan Mundipharma Pharmaceuticals Ltd.